These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

227 related articles for article (PubMed ID: 23425270)

  • 1. Nonclinical development of a biosimilar: the current landscape.
    O'Connor A; Rogge M
    Bioanalysis; 2013 Mar; 5(5):537-44. PubMed ID: 23425270
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A wide angle view of biosimilars from a bioanalytical perspective.
    Oldfield P
    Bioanalysis; 2013 Mar; 5(5):533-5. PubMed ID: 23425269
    [No Abstract]   [Full Text] [Related]  

  • 3. Analytical and bioanalytical assay challenges to support comparability studies for biosimilar drug development.
    Cai XY; Wake A; Gouty D
    Bioanalysis; 2013 Mar; 5(5):517-20. PubMed ID: 23425265
    [No Abstract]   [Full Text] [Related]  

  • 4. Clinical development of biosimilars: an evolving landscape.
    Subramanyam M
    Bioanalysis; 2013 Mar; 5(5):575-86. PubMed ID: 23425273
    [TBL] [Abstract][Full Text] [Related]  

  • 5. European perspective on biosimilars.
    Wadhwa M; Thorpe R
    Bioanalysis; 2013 Mar; 5(5):521-4. PubMed ID: 23425266
    [No Abstract]   [Full Text] [Related]  

  • 6. The US approach to biosimilars: the long-awaited FDA approval pathway.
    Calvo B; Zuñiga L
    BioDrugs; 2012 Dec; 26(6):357-61. PubMed ID: 23030677
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Biosimilars: impact of biologic product life cycle and European experience on the regulatory trajectory in the United States.
    Ahmed I; Kaspar B; Sharma U
    Clin Ther; 2012 Feb; 34(2):400-19. PubMed ID: 22244050
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Bioanalytical challenges of biosimilars.
    Islam R
    Bioanalysis; 2014 Feb; 6(3):349-56. PubMed ID: 24471955
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Biosimilars: Rationale and current regulatory landscape.
    Olech E
    Semin Arthritis Rheum; 2016 Apr; 45(5 Suppl):S1-10. PubMed ID: 26947438
    [TBL] [Abstract][Full Text] [Related]  

  • 10. An update on the animal studies conducted for biosimilar approvals - Regulatory requirement vs actual scenario.
    Pipalava P; Patel R; Mehta M; Dahiya M; Singh I; Jose V
    Regul Toxicol Pharmacol; 2019 Oct; 107():104415. PubMed ID: 31254556
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Progress in biosimilar monoclonal antibody development: the infliximab biosimilar CT-P13 in the treatment of rheumatic diseases.
    Braun J; Kudrin A
    Immunotherapy; 2015; 7(2):73-87. PubMed ID: 25713985
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ten years of biosimilars in Europe: development and evolution of the regulatory pathways.
    Schiestl M; Zabransky M; Sörgel F
    Drug Des Devel Ther; 2017; 11():1509-1515. PubMed ID: 28553082
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Key considerations in the preclinical development of biosimilars.
    Bui LA; Hurst S; Finch GL; Ingram B; Jacobs IA; Kirchhoff CF; Ng CK; Ryan AM
    Drug Discov Today; 2015 May; 20 Suppl 1():3-15. PubMed ID: 25912284
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Scientific considerations for assessing biosimilar products.
    Chow SC; Wang J; Endrenyi L; Lachenbruch PA
    Stat Med; 2013 Feb; 32(3):370-81. PubMed ID: 22933240
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Conference Report: Bioanalysis-related topics presented at the International Conference and Exhibition on Biowaivers and Biosimilars.
    Colletti KS
    Bioanalysis; 2013 Mar; 5(5):529-31. PubMed ID: 23425268
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comments on the FDA draft guidance on biosimilar products.
    Chow SC; Endrenyi L; Lachenbruch PA
    Stat Med; 2013 Feb; 32(3):364-9. PubMed ID: 22903309
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mini Focus: bioanalysis of biosimilars.
    Amaravadi L; Marini J
    Bioanalysis; 2013 Mar; 5(5):515-6. PubMed ID: 23425264
    [No Abstract]   [Full Text] [Related]  

  • 18. Challenges of developing and validating immunogenicity assays to support comparability studies for biosimilar drug development.
    Cai XY; Thomas J; Cullen C; Gouty D
    Bioanalysis; 2012 Sep; 4(17):2169-77. PubMed ID: 23013399
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Considerations of critical quality attributes in the analytical comparability assessment of biosimilar products.
    Kwon O; Joung J; Park Y; Kim CW; Hong SH
    Biologicals; 2017 Jul; 48():101-108. PubMed ID: 28495312
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Developing clinical trials for biosimilars.
    Bui LA; Taylor C
    Semin Oncol; 2014 Feb; 41 Suppl 1():S15-25. PubMed ID: 24560024
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.